REG - Oxford Biomedica PLC - Total Voting Rights <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

01/12/2017 10:20

RNS Number : 1367Y
Oxford Biomedica PLC
01 December 2017
Oxford BioMedica 
Total Voting Rights
Oxford, UK - 1 December 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 30 November 2017 consisted of 3,107,136,542 ordinary shares of 1 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury. 
Accordingly, the total number of voting rights in Oxford BioMedica plc at the date of this notice is 3,107,136,542.
The above figure (3,107,136,542) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford BioMedica plc under the FCA's Disclosure and Transparency Rules.
- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector) through which the Group developsin vivoandex vivoproducts both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available atwww.oxfordbiomedica.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
TVREAEAFEFLXFFF